CN107502592A - A kind of immunocyte serum free medium and preparation method thereof - Google Patents
A kind of immunocyte serum free medium and preparation method thereof Download PDFInfo
- Publication number
- CN107502592A CN107502592A CN201710953958.6A CN201710953958A CN107502592A CN 107502592 A CN107502592 A CN 107502592A CN 201710953958 A CN201710953958 A CN 201710953958A CN 107502592 A CN107502592 A CN 107502592A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- medium
- serum free
- free medium
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012679 serum free medium Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 10
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 9
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 8
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000367 inositol Drugs 0.000 claims abstract description 6
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 6
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 5
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 5
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 5
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims abstract description 5
- 229920000768 polyamine Polymers 0.000 claims abstract description 5
- 102000004877 Insulin Human genes 0.000 claims abstract description 4
- 108090001061 Insulin Proteins 0.000 claims abstract description 4
- 229940125396 insulin Drugs 0.000 claims abstract description 4
- 239000001963 growth medium Substances 0.000 claims description 9
- 102100037850 Interferon gamma Human genes 0.000 claims description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000007640 basal medium Substances 0.000 claims description 4
- 229960002989 glutamic acid Drugs 0.000 claims description 4
- 239000012533 medium component Substances 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- 229930003571 Vitamin B5 Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 235000013930 proline Nutrition 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 229940054269 sodium pyruvate Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 235000002374 tyrosine Nutrition 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 239000011675 vitamin B5 Substances 0.000 claims description 2
- 235000009492 vitamin B5 Nutrition 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 1
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- CCHNOBQMQBSRHQ-UHFFFAOYSA-N phosphoric acid;7h-purin-6-amine Chemical compound OP(O)(O)=O.NC1=NC=NC2=C1NC=N2 CCHNOBQMQBSRHQ-UHFFFAOYSA-N 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 abstract description 14
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 abstract description 12
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 abstract description 12
- 210000002865 immune cell Anatomy 0.000 abstract description 7
- 238000009169 immunotherapy Methods 0.000 abstract description 4
- 239000004017 serum-free culture medium Substances 0.000 abstract description 4
- 230000004913 activation Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 238000003908 quality control method Methods 0.000 abstract description 3
- 229940107161 cholesterol Drugs 0.000 abstract description 2
- 229960002413 ferric citrate Drugs 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 27
- 239000002609 medium Substances 0.000 description 20
- -1 IL-1α Proteins 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 240000006162 Chenopodium quinoa Species 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011177 media preparation Methods 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000015493 Chenopodium quinoa Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003776 Vitamin B4 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 239000011579 vitamin B4 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种免疫细胞无血清培养基及其制备方法。本发明的无血清培养基的主要成分为:聚胺、胰岛素、胆固醇、枸橼酸铁、肌醇和抗氧化剂和白细胞介素15。本发明的无血清培养基对人体安全,能提高CIK细胞增殖速度和活化率。并且有成分简单、性状稳定、批间差异小、便于质控、诱导CIK增殖效率高、CD3+CD56+的阳性比例高,培养获得的CIK细胞质量稳定的优点,对于免疫治疗的推广应用具有重要意义。The invention discloses an immune cell serum-free culture medium and a preparation method thereof. The main components of the serum-free medium of the present invention are: polyamine, insulin, cholesterol, ferric citrate, inositol, antioxidant and interleukin-15. The serum-free culture medium of the invention is safe for human body and can increase the proliferation speed and activation rate of CIK cells. And it has the advantages of simple ingredients, stable properties, small batch-to-batch difference, convenient quality control, high efficiency of inducing CIK proliferation, high positive ratio of CD3 + CD56 + , and stable quality of CIK cells obtained by culture, which is of great importance for the promotion and application of immunotherapy significance.
Description
技术领域technical field
本发明属于生物医学技术领域,具体涉及一种免疫细胞无血清培养基及其制备方法和用途。The invention belongs to the technical field of biomedicine, and in particular relates to a serum-free culture medium for immune cells and its preparation method and application.
背景技术Background technique
细胞因子诱导的肿瘤杀伤细胞(CIKs)是将人外周血单个核细胞在体外用多种细胞因子共同培养而获得的一群异质细胞群,因其兼具有T淋巴细胞强大的抗瘤活性和NK细胞的非主要组织相容抗原(MHC)限制性杀瘤特点,从而成为肿瘤过继免疫治疗的重要手段之一。CIK细胞由于具有较强的增生能力和细胞毒性且杀瘤谱广而受到广泛的重视,在一些实体瘤、血液肿瘤及血液病骨髓移植后的免疫治疗中已显示出良好的应用前景。能否获得足够数量的效应细胞及效应细胞的杀伤活性与CIK细胞治疗的临床疗效有着密切的关系。研究已表明,CIK的主要效应细胞为CD3+/CD56+双阳性细胞。CIK细胞培养后CD3+/CD56+细胞所占细胞总数的比例是重要观察指标。Cytokine-induced tumor killer cells (CIKs) are a group of heterogeneous cell populations obtained by co-culturing human peripheral blood mononuclear cells with various cytokines in vitro, because they have both strong anti-tumor activity of T lymphocytes and The non-major histocompatibility antigen (MHC)-restricted tumor killing characteristics of NK cells have become one of the important means of tumor adoptive immunotherapy. CIK cells have received extensive attention due to their strong proliferative ability, cytotoxicity and broad tumor killing spectrum. They have shown good application prospects in the immunotherapy of some solid tumors, hematological tumors and hematological diseases after bone marrow transplantation. Whether a sufficient number of effector cells can be obtained and the killing activity of effector cells are closely related to the clinical efficacy of CIK cell therapy. Studies have shown that the main effector cells of CIK are CD3+/CD56+ double positive cells. The ratio of CD3+/CD56+ cells to the total number of cells after CIK cell culture is an important observation index.
传统对CIK细胞治疗的通用流程是将患者外周血中采集的单个核细胞在体外经IFN-γ、CD3单抗、IL-1α以及IL-2修饰、刺激、培养、增殖后回输到患者体内,从而杀伤肿瘤。目前培养方法细胞增殖慢、倍增时间长、CD3+/CD56+双阳性细胞比率不稳定。大部分实验室体外培养人免疫细胞主要以添加人AB血清或FBS来维持免疫细胞生长。但动物或人血清中含有病原体或不确定物质,再加上人AB血清来源困难,会对培养细胞带来危险或不确定的危害。并且传统培养基成分不稳定无法进行后期质量控制,无法在工业上大规模生产。因此亟需开发能克服上述缺陷的无血清培养基。The general process of traditional CIK cell therapy is to infuse the mononuclear cells collected from the patient's peripheral blood into the patient after being modified, stimulated, cultured and proliferated by IFN-γ, CD3 monoclonal antibody, IL-1α and IL-2 in vitro , thereby killing the tumor. The current culture method has slow cell proliferation, long doubling time, and unstable ratio of CD3+/CD56+ double positive cells. Most laboratories culture human immune cells in vitro mainly by adding human AB serum or FBS to maintain the growth of immune cells. However, animal or human serum contains pathogens or uncertain substances, and the source of human AB serum is difficult, which will bring dangerous or uncertain hazards to cultured cells. Moreover, the components of the traditional culture medium are unstable and cannot be used for quality control in the later stage, and cannot be mass-produced in industry. Therefore, there is an urgent need to develop a serum-free medium that can overcome the above-mentioned defects.
发明内容Contents of the invention
本发明的目的在于提供一种免疫细胞无血清培养基及其制备方法和用途。该培养基对人体安全,并能提高CIK细胞表型(CD3+CD56+)双阳性率的培养基。The object of the present invention is to provide an immune cell serum-free culture medium and its preparation method and application. The culture medium is safe for human body and can increase the double-positive rate of CIK cell phenotype (CD3+CD56+).
一种免疫细胞无血清培养基,培养基成分包括基础培养基、聚胺、胰岛素、胆固醇、枸橼酸铁、肌醇和抗氧化剂;所述基础培养基是RPMI-1640。An immune cell serum-free medium, the medium components include basal medium, polyamine, insulin, cholesterol, ferric citrate, inositol and antioxidant; the basal medium is RPMI-1640.
每升培养基包括:胆固醇13.2mg/L;胰岛素20mg/L;枸橼酸铁2mg/L;NaHCO3 2g/L;乙醇胺1.22mg/L;亚油酸1mg/L;肌醇19mg/L;左旋谷氨酸584mg/L;丙酮酸钠110mg/L;2巯基乙醇0.78mg/L;1硫代甘油5.41mg/L;非必须氨基酸20ml/L;维生素10ml/L;聚胺添加物3.31mg/L;抗氧化剂0.52mg/L;油酸1mg/L。Each liter of medium includes: cholesterol 13.2mg/L; insulin 20mg/L; iron citrate 2mg/L; NaHCO 3 2g/L; ethanolamine 1.22mg/L; linoleic acid 1mg/L; inositol 19mg/L; L-glutamic acid 584mg/L; sodium pyruvate 110mg/L; 2-mercaptoethanol 0.78mg/L; 1-thioglycerol 5.41mg/L; non-essential amino acid 20ml/L; vitamin 10ml/L; polyamine additive 3.31mg /L; antioxidant 0.52mg/L; oleic acid 1mg/L.
所述非必须氨基酸为甘氨酸、丙氨酸、脯氨酸、酪氨酸、丝氨酸、半胱氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸中的一种或一种以上。The non-essential amino acid is one or one of glycine, alanine, proline, tyrosine, serine, cysteine, asparagine, glutamine, aspartic acid, glutamic acid above.
所述维生素为维生素A,维生素B1,维生素B2,维生素PP,维生素B4,维生素B5,维生素B6,生物素,维生素B9,维生素B12,肌醇,维生素C,维生素D,维生素E,维生素K中的一种或一种以上。The vitamins are vitamin A, vitamin B1, vitamin B2, vitamin PP, vitamin B4, vitamin B5, vitamin B6, biotin, vitamin B9, vitamin B12, inositol, vitamin C, vitamin D, vitamin E, vitamin K One or more than one.
所述培养基成分还包括IL-15(白细胞介素15),IFN-γ,CD3,IL-1α,IL-2因子中的一种或一种以上。The medium components also include one or more of IL-15 (interleukin-15), IFN-γ, CD3, IL-1α, and IL-2 factors.
本发明的有益效果:本发明的无血清培养基对人体安全,能稳定CIK细胞增殖速度和提高细胞CD3+CD56+,并且有成分简单、性状稳定、批间差异小、便于质控、诱导CIK增殖效率高、CD3+CD56+的阳性比例高,培养获得的CIK细胞质量稳定的优点,对于免疫治疗的推广应用具有重要意义。Beneficial effects of the present invention: the serum-free medium of the present invention is safe for human body, can stabilize CIK cell proliferation rate and increase cell CD3 + CD56 + , and has simple ingredients, stable properties, small batch-to-batch difference, convenient quality control, and induction of CIK The advantages of high proliferation efficiency, high CD3 + CD56 + positive ratio, and stable quality of CIK cells obtained from culture are of great significance for the promotion and application of immunotherapy.
附图说明Description of drawings
图1为1-3号培养基与实施例1的无血清培养基培养的CIK细胞表型流式细胞术检测结果对比图;Fig. 1 is the comparative figure of the CIK cell phenotype flow cytometry detection result that culture medium No. 1-3 and the serum-free medium of embodiment 1 cultivate;
图2为实施例1的无血清培养基与Takara公司的H3培养基培养的CIK细胞表型流式细胞术检测结果对比图。Fig. 2 is a comparison chart of flow cytometry detection results of CIK cell phenotypes cultured in the serum-free medium of Example 1 and the H3 medium of Takara Company.
图3为实施例1的无血清培养基在添加IL-15之后,CIK细胞表型流式细胞术检测结果对比图。Fig. 3 is a comparison chart of CIK cell phenotype flow cytometry detection results after IL-15 is added to the serum-free medium in Example 1.
具体实施方式detailed description
下面结合附图和具体实施例对本发明做进一步说明。The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.
实施例1Example 1
将一袋一升装RPMI 1640(Gibco)用超纯水搅拌溶解,依次加入下表所添加物质(表1),最终定容至1L,搅拌溶解,调节PH值至7.0左右,0.22μm滤膜过滤除菌,4℃保存。其中pH值保持在6.8-7.2之间,最佳pH值保持在7.0。Stir and dissolve a bag of 1 liter RPMI 1640 (Gibco) with ultrapure water, add the substances added in the following table (Table 1) in sequence, and finally set the volume to 1L, stir and dissolve, adjust the pH value to about 7.0, and use a 0.22μm filter membrane Sterilize by filtration and store at 4°C. Wherein the pH value is kept between 6.8-7.2, and the optimum pH value is kept at 7.0.
表1.免疫细胞无血清培养基配制表Table 1. Preparation of serum-free medium for immune cells
取患者外周血60ml,转入2支50ml离心管,2200rpm离心10min,吸取上层黄色血浆,转移至新的50ml离心管中,置于56℃灭活25min,4℃冷藏10min,3000rpm,4℃,离心15min,取上清分装后置于4℃保存备用。将下层红细胞缓缓加入已装有淋巴细胞分离液的2支50ml离心管中,400g离心30min。取中间层白色细胞,NaCl清洗2次后,将细胞种于1-4号的培养基中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。Take 60ml of peripheral blood from the patient, transfer it to two 50ml centrifuge tubes, centrifuge at 2200rpm for 10min, absorb the upper yellow plasma, transfer to a new 50ml centrifuge tube, inactivate at 56°C for 25min, refrigerate at 4°C for 10min, 3000rpm, 4°C, After centrifugation for 15 min, the supernatant was collected and stored at 4°C for later use. Slowly add the red blood cells in the lower layer to two 50ml centrifuge tubes filled with lymphocyte separation medium, and centrifuge at 400g for 30min. Take the white cells in the middle layer, wash them twice with NaCl, plant the cells in No. 1-4 medium, add IFN-γ, CD3, IL-1α, and IL-2 factors, and continue to culture for 14 days.
1号培养基:RPMI 1640。Medium No. 1: RPMI 1640.
2号培养基:RPMI 1640+白蛋白。Medium 2: RPMI 1640+albumin.
3号培养基:RPMI 1640+UltraKURE。Medium 3: RPMI 1640+UltraKURE.
4号培养基:RPMI 1640+表一配方(C922)。Medium No. 4: RPMI 1640+Formulation in Table 1 (C922).
实施例2Example 2
前面培养基配制步骤和细胞培养步骤同实施例1。将细胞种于H3和培养基中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。比较Takara商品化的H3培养基与我们本实施例培养基对于细胞增值率、存活率和细胞表型方面的影响。The preceding medium preparation steps and cell culture steps are the same as in Example 1. The cells were planted in H3 and medium, and IFN-γ, CD3, IL-1α, IL-2 factors were added, and the culture was continued for 14 days. Compare the effects of Takara's commercialized H3 medium and our medium in this example on cell proliferation rate, survival rate and cell phenotype.
实施例3Example 3
前面培养基配制步骤和细胞培养步骤同实施例1。将细胞种于培养基和培养基外加白介素15(0.5ng/mL)中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。比较IL-15对我们本发明培养基对于细胞增值率、存活率和细胞表型方面的影响。The preceding medium preparation steps and cell culture steps are the same as in Example 1. The cells were planted in the medium and the medium plus interleukin 15 (0.5ng/mL), and IFN-γ, CD3, IL-1α, IL-2 factors were added, and the culture was continued for 14 days. Compare the effects of IL-15 on our culture medium of the present invention on cell proliferation rate, survival rate and cell phenotype.
验结果表明,在培养14天后,CD3+CD56+双阳性细胞百分率:1-3号组均小于3%,4号培养基为27.2%(图1)。与商品化的H3对比,与H3组的细胞扩增率差不多,细胞存活率都在98%左右。但在细胞表型方面,H3组CD3+CD56+双阳性细胞百分率为17.3%,而4号培养基为23.7%(图2)。比H3提高了6个百分点。在4号培养基中添加了IL-15(0.5ng/mL)可以有效提高CD3+CD56+双阳性细胞百分率,CIK细胞活化率提高了一倍以上(图3)。The experimental results showed that after 14 days of culture, the percentage of CD3 + CD56 + double-positive cells: groups 1-3 were all less than 3%, and culture medium 4 was 27.2% (Fig. 1). Compared with the commercialized H3, the cell expansion rate of the H3 group is almost the same, and the cell survival rate is about 98%. But in terms of cell phenotype, the percentage of CD3 + CD56 + double-positive cells in H3 group was 17.3%, while that in No. 4 medium was 23.7% (Fig. 2). 6 percentage points higher than H3. Adding IL-15 (0.5ng/mL) to No. 4 medium can effectively increase the percentage of CD3 + CD56 + double-positive cells, and the activation rate of CIK cells has more than doubled (Figure 3).
实施例4Example 4
前面培养基配制步骤和细胞培养步骤同实施例1。将细胞种于培养基和培养基外加苞藜提取物(3mg/L)中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。比较苞藜提取物对我们本发明培养基对于细胞增值率、存活率和细胞表型方面的影响。The preceding medium preparation steps and cell culture steps are the same as in Example 1. The cells were planted in the medium and the medium plus the extract of Chenopodium quinoa (3mg/L), and IFN-γ, CD3, IL-1α, IL-2 factors were added, and the culture was continued for 14 days. To compare the effect of the extract of quinoa quinoa on our culture medium of the present invention on cell proliferation rate, survival rate and cell phenotype.
所述苞藜提取物的提取方法如下:将苞藜提取物叶片晒干,加3-5倍重量份数的水溶液回流提取3次,合并滤液,蒸干制成。The extraction method of the quinoa quinoa extract is as follows: dry the leaves of the quinoa quinoa extract, add 3-5 times the weight of the aqueous solution to reflux for extraction three times, combine the filtrates, and evaporate to dryness.
实施例5Example 5
前面培养基配制步骤和细胞培养步骤同实施例1。将细胞种于培养基和培养基外加环磷酰胺中,并添加IFN-γ,CD3,IL-1α,IL-2因子,继续培养14天。比较环磷酰胺IL-15对我们本发明培养基对于细胞增值率、存活率和细胞表型方面的影响。The preceding medium preparation steps and cell culture steps are the same as in Example 1. The cells were seeded in the medium and the medium plus cyclophosphamide, and IFN-γ, CD3, IL-1α, IL-2 factors were added, and the culture was continued for 14 days. Compare the effects of cyclophosphamide IL-15 on our culture medium of the present invention on cell proliferation rate, survival rate and cell phenotype.
验结果表明,在培养14天后,CD3+CD56+双阳性细胞百分率:4号培养基为27.2%(图1),实施例4为36.2%,实施例5为37.1%。在4号培养基中添加苞藜提取物和环磷酰胺可以有效提高CD3+CD56+双阳性细胞百分率,CIK细胞活化率提高一倍以上。The experimental results showed that after 14 days of culture, the percentage of CD3 + CD56 + double-positive cells: No. 4 culture medium was 27.2% (Fig. 1), Example 4 was 36.2%, and Example 5 was 37.1%. Adding quinoa quinoa extract and cyclophosphamide to No. 4 medium can effectively increase the percentage of CD3 + CD56 + double-positive cells, and the activation rate of CIK cells is more than doubled.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710953958.6A CN107502592A (en) | 2017-10-13 | 2017-10-13 | A kind of immunocyte serum free medium and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710953958.6A CN107502592A (en) | 2017-10-13 | 2017-10-13 | A kind of immunocyte serum free medium and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107502592A true CN107502592A (en) | 2017-12-22 |
Family
ID=60700984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710953958.6A Pending CN107502592A (en) | 2017-10-13 | 2017-10-13 | A kind of immunocyte serum free medium and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107502592A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109593712A (en) * | 2018-12-24 | 2019-04-09 | 广东暨德康民生物科技有限责任公司 | Immune cell expansion method and immune cell media |
CN108004213B (en) * | 2018-01-30 | 2020-09-22 | 北京汇智驰康生物科技有限公司 | Method and kit for rapid amplification of CIK cells |
CN112029723A (en) * | 2020-09-18 | 2020-12-04 | 郑州佐爵生物科技有限公司 | Method for culturing umbilical cord blood CIK cells in vitro |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1566331A (en) * | 2003-06-27 | 2005-01-19 | 北京天润善达生物科技有限责任公司 | Serum-free culture medium for lymphocyte |
CN104371973A (en) * | 2013-08-15 | 2015-02-25 | 协和华东干细胞基因工程有限公司 | Serum-free medium of immune cells |
CN105018423A (en) * | 2015-05-27 | 2015-11-04 | 贵州北科泛特尔生物科技有限公司 | CIK cell culturing method |
WO2016091349A1 (en) * | 2014-12-11 | 2016-06-16 | Merck Patent Gmbh | Cell culture media |
CN106635953A (en) * | 2016-12-13 | 2017-05-10 | 昆明润什生物科技有限公司 | Serum-free protein-free cell culture medium |
CN106754634A (en) * | 2016-12-31 | 2017-05-31 | 山东金周生物科技有限公司 | A kind of serum free medium and preparation method thereof |
CN106834229A (en) * | 2017-01-25 | 2017-06-13 | 华东理工大学 | For the serum free medium of people's immunologic cytotoxicity cell expansion ex vivo |
-
2017
- 2017-10-13 CN CN201710953958.6A patent/CN107502592A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1566331A (en) * | 2003-06-27 | 2005-01-19 | 北京天润善达生物科技有限责任公司 | Serum-free culture medium for lymphocyte |
CN104371973A (en) * | 2013-08-15 | 2015-02-25 | 协和华东干细胞基因工程有限公司 | Serum-free medium of immune cells |
WO2016091349A1 (en) * | 2014-12-11 | 2016-06-16 | Merck Patent Gmbh | Cell culture media |
CN105018423A (en) * | 2015-05-27 | 2015-11-04 | 贵州北科泛特尔生物科技有限公司 | CIK cell culturing method |
CN106635953A (en) * | 2016-12-13 | 2017-05-10 | 昆明润什生物科技有限公司 | Serum-free protein-free cell culture medium |
CN106754634A (en) * | 2016-12-31 | 2017-05-31 | 山东金周生物科技有限公司 | A kind of serum free medium and preparation method thereof |
CN106834229A (en) * | 2017-01-25 | 2017-06-13 | 华东理工大学 | For the serum free medium of people's immunologic cytotoxicity cell expansion ex vivo |
Non-Patent Citations (1)
Title |
---|
徐厚冰: "《菠菜提取物》", 《百度百科》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108004213B (en) * | 2018-01-30 | 2020-09-22 | 北京汇智驰康生物科技有限公司 | Method and kit for rapid amplification of CIK cells |
CN109593712A (en) * | 2018-12-24 | 2019-04-09 | 广东暨德康民生物科技有限责任公司 | Immune cell expansion method and immune cell media |
CN112029723A (en) * | 2020-09-18 | 2020-12-04 | 郑州佐爵生物科技有限公司 | Method for culturing umbilical cord blood CIK cells in vitro |
CN112029723B (en) * | 2020-09-18 | 2021-08-06 | 陕西中港万海生命科学研究院有限公司 | Method for culturing umbilical cord blood CIK cells in vitro |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080292605A1 (en) | Materials for stimulation of hematopoiesis by ex vivo activated cells | |
CN106190964B (en) | A serum-free medium for mesenchymal stem cells | |
CN107267454A (en) | The amplification in vitro method and its kit of a kind of Cord Blood Natural Killer Cells: Impact and application | |
CN104928241B (en) | A kind of activation method and cell preparation method of enhanced NK cells | |
CN107502592A (en) | A kind of immunocyte serum free medium and preparation method thereof | |
EP3114215A1 (en) | Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease | |
CN105524882B (en) | Serum substitute for immunologic cytotoxicity cell expansion ex vivo combines | |
CN112795536A (en) | Culture method of human T cells and serum-free medium composition | |
JP2022504722A (en) | Proliferation system for hematopoietic stem cells and hematopoietic progenitor cells | |
Pochon et al. | Wharton’s jelly‐derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation | |
Najar et al. | Cytokinome of adult-derived human liver stem/progenitor cells: immunological and inflammatory features | |
US20020159984A1 (en) | Cultivation of cells for long term engraftment | |
US20220396766A1 (en) | Method for arterial endothelial-enhanced functional t cell generation | |
WO2022143785A1 (en) | Methods for preparing tumor-infiltrating lymphocytes | |
CN118667759A (en) | NK cell serum-free medium | |
CN104017770B (en) | Method for preparing CIK cell by using glycolipid | |
CN107502589A (en) | A kind of tumor infiltrating lymphocyte and mononuclearcell co-culture method | |
CN114517176B (en) | Kit for inducing IPS (in-plane switching) cells into NK (natural killer) cells and application method of kit | |
CN103966163B (en) | Enhancement mode DCIK cell preparation method and cell preparation thereof | |
CN115044548B (en) | Serum-free medium and application thereof | |
CN113652400B (en) | NK cell serum-free medium and application thereof | |
US7332158B2 (en) | Compositions and treatments for myelosuppression by ex vivo activated immune cells | |
CN104673746B (en) | Bone photo closes mescenchymal stem cell Sca1+The preparation and its application of subgroup | |
CN107090434A (en) | A kind of blood anticoagulant and store method for improving CIK cell culture effect | |
CN118773134B (en) | CIK cell culture solution suitable for CIK cell culture and method for culturing CIK cells by using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |